Company: DERM
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001410578-25-000490
Chunk: 10

Company: Journey Medical Corp
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 10
---
.gov.

Our Market, Products and Relevant Disease States

Our major marketed products, which have been approved by the FDA for sale in the United States, include:

●EmrosiTM (Minocycline Hydrochloride Extended Release Capsules, 40 mg for the treatment of inflammatory lesions of rosacea in adults), approved by the FDA in November 2024, sales promotion beginning in April 2025.

●Qbrexza® (a medicated cloth towelette for the treatment of primary axillary hyperhidrosis in patients nine years of age and older), acquired and launched in May 2021;

●Accutane® (an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne), licensed in July 2020 and launched in March 2021;

●Amzeeq® (minocycline) topical foam, 4% (a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older), acquired and launched in January 2022;

●Zilxi® (minocycline) topical foam, 1.5% (a topical minocycline treatment for inflammatory lesions of rosacea in adults), acquired and launched in January 2022;